RxDoctor Payments Data

Joseph Alia, DO

Family Medicine · Tempe, AZNPI 1265424584

Payments from drug & device makers

$8,285in general payments, 2019–2025

Across 487 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$796
  • AbbVie$773
  • Amgen$725
  • Boehringer Ingelheim$616
  • Lilly USA, LLC$534
  • Novo Nordisk$480
  • plus $4K from 47 others

What the payments were for

  • Food & beverage$8,267100%
  • Entertainment$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,285 in reported general payments places this provider in the 90th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$131,423
Medicare patients
289
Services billed
2,306

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin120$119,096
OzempicSemaglutide88$103,877
JanuviaSitagliptin Phosphate67$69,642
LinzessLinaclotide83$63,180
FarxigaDapagliflozin Propanediol57$54,538
TrulicityDulaglutide48$47,896
EliquisApixaban52$39,805
XareltoRivaroxaban29$28,471
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog40$27,986
TradjentaLinagliptin32$18,933
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$17,658
MounjaroTirzepatide15$15,192
SavellaMilnacipran Hcl13$12,518
MyrbetriqMirabegron18$12,517
Tresiba Flextouch U-100Insulin Degludec22$10,454

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$616$138,029152 claims
Novo NordiskOzempic$480$103,87788 claims
AbbVieLinzess, Savella$773$75,69896 claims
MerckJanuvia$240$69,64267 claims
Lilly USA, LLCTrulicity, Mounjaro$534$63,08863 claims
AstraZenecaFarxiga, Symbicort$796$58,64971 claims
PfizerEliquis$406$39,80552 claims
Johnson & JohnsonXarelto$176$28,47129 claims
GSKTrelegy Ellipta, Breo Ellipta$430$24,15231 claims
Astellas Pharma US IncMyrbetriq$70$12,51718 claims
Esperion Therapeutics, Inc.Nexletol$131$8,92419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Tempe

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →